Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C
Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C
复制标题
DOI：
10.1111/jvh.12737
复制
发表时间：
2017-12-01
影响因子：
2.5
通讯作者：
Sakamoto, N.
中科院分区：
文献类型：
--
作者：
Kawagishi, N.;Suda, G.;Sakamoto, N.
有报道称，丙型肝炎病毒(丙型肝炎病毒)和乙肝病毒混合感染的患者在抗丙型肝炎治疗过程中，乙肝病毒(乙肝病毒)重新激活。我们的目的是评估在抗丙型肝炎病毒治疗中乙肝病毒重新激活的频率和危险因素，并比较不含干扰素的直接作用抗病毒(DAA)治疗和基于干扰素的治疗。对322例丙型肝炎病毒感染者进行了抗丙型肝炎病毒治疗的回顾性筛查。在治疗结束时，检查所有符合条件的患者的基线乙肝病毒感染状态，以及所有现在或以前感染过乙肝病毒的患者的HBVDNA水平。在基线抗-HBs阳性的患者中，评估抗-HBs滴度的变化。在符合纳入标准的287名患者中，157人目前(n=4)或以前(n=153)感染了乙肝病毒；85人接受了不含干扰素的DAA治疗，72人接受了基于干扰素的治疗。在不含干扰素的DAA治疗后，6例患者出现了乙肝病毒再激活(n=2)或再次出现乙肝病毒(n=4)，而在以干扰素为基础的治疗后，没有患者出现乙肝病毒再激活。乙肝病毒重新激活或再次出现的危险因素是DAA治疗和抗-HBs滴度降低。
Hepatitis B virus (HBV) reactivation has been reported during antihepatitis C treatment in patients with hepatitis C virus (HCV) and HBV co-infection. We aimed to evaluate the frequency and risk factors of HBV reactivation during anti-HCV therapy and compared those between interferon (IFN)-free direct-acting antiviral (DAA) therapies and IFN-based therapies. Three hundred and twenty-two patients with HCV infection receiving anti-HCV therapy were retrospectively screened. The baseline HBV infection statuses of all eligible patients and the HBV-DNA level of all patients with current or previous HBV infection were examined at the end of treatment. In patients with baseline anti-HBs positivity, changes in anti-HBs titre were evaluated. Of 287 patients who met the inclusion criteria, 157 had current (n=4) or previous (n=153) HBV infection; 85 were treated with IFN-free DAA therapies and 72 were treated with IFN-based therapies. Six patients experienced HBV reactivation (n=2) or HBV reappearance (n=4) after IFN-free DAA therapies, while no patient developed HBV reactivation after IFN-based therapies. The risk factors of HBV reactivation or reappearance were DAA therapies and a reduction in anti-HBs titre to